Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis COX-189 TARGET Study Will Assess CV Safety Of COX-2 Inhibitor

Executive Summary

Novartis' long-term COX-2 inhibitor safety study will be sufficiently large to provide "clear" evidence of the cardiovascular safety of COX-189, Clinical R&D Head James Shannon told analysts in New York City Oct. 30

You may also be interested in...



Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis

Novartis' TARGET study found that the COX-2 inhibitor Prexige has approximately one-third the rate of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs

Prexige TARGET Study: Not Quite A Bull’s-Eye For Novartis

Novartis' TARGET study found that the COX-2 inhibitor Prexige has approximately one-third the rate of gastrointestinal side effects compared to non-steroidal anti-inflammatory drugs

Novartis Prexige Is “Not Approvable;” COX-2 Launch At Least Two Years Away

The liver safety profile of Novartis' Prexige appears to be one factor behind FDA's request for additional studies on the COX-2 inhibitor prior to approval in osteoarthritis and acute pain

Related Content

UsernamePublicRestriction

Register

PS038833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel